These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8468725)

  • 1. Effect of high-protein diet on pyrimidine synthesis and response to PALA in mouse tissues.
    Zaharevitz DW; Grubb MF; Hyman R; Chisena C; Cysyk RL
    J Natl Cancer Inst; 1993 Apr; 85(8):662-6. PubMed ID: 8468725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of de-novo and salvage synthesis to the uracil nucleotide pool in mouse tissues and tumors in vivo.
    Zaharevitz DW; Anderson LW; Malinowski NM; Hyman R; Strong JM; Cysyk RL
    Eur J Biochem; 1992 Nov; 210(1):293-6. PubMed ID: 1446677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of low-dose PALA in biochemical modulation.
    O'Dwyer PJ
    Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
    Karle JM; Cowan KH; Chisena CA; Cysyk RL
    Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of uracil nucleotide synthesis in mouse liver, intestine and kidney by ammonium chloride infusion.
    Zaharevitz DW; Napier EA; Anderson LW; Strong JM; Cysyk RL
    Eur J Biochem; 1988 Jul; 175(1):193-8. PubMed ID: 3402448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
    Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
    Martin DS; Kemeny NE
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based model for tumor drug resistance.
    Kuczek T; Chan TC
    Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.